Pregnancy brings unique microbiome changes that impact both mother and baby. Prenatis™ is a scientifically validated probiotic solution designed to support vaginal health during pregnancy and promote healthy gut microbiota in newborns.
Study Design
- Type: Randomized, double-blind, placebo-controlled trial
- Participants: 180 healthy pregnant women in their 3rd trimester (≥28 weeks)
- Intervention: Prenatis™ (5B CFU/day) vs. placebo
- Duration: Prenatal: 12 weeks / Postnatal: 4–6 weeks
- Follow-up: Infants monitored until 1 year old
Key Benefits
- For Mothers
- Helps maintain a balanced vaginal microbiome during pregnancy.
- Reduces the proportion of women with at least one diagnosed infection
- 8.9% infections with Prenatis™ vs. 20% with placebo (p = 0.05).
- Trend toward lower bacterial vaginosis incidence (6.7% vs. 13.3%).
- For Babies
- Fewer sick days: Infants had infections lasting 6 days less on average when mothers took Prenatis™ (p = 0.03).
- Healthier gut microbiome:
- Bifidobacteria detected in 85% of infants vs. 64% in placebo group.
- Significant reduction in opportunistic bacteria like Enterococci and Escherichia/Shigella.
- Supports microbiome development in C-section and breastfed infants.
Scientific Highlights
- Large, high-quality mother–infant cohort study.
- Safe for pregnant women and babies.
- Proprietary strains with proven efficacy for natural defenses and women’s health.
- Positive impact on natural defenses and microbiome vertical transmission.
Why It Matters
- C-section rates are rising globally (WHO predicts up to 32% by 2030).
- Prenatis™ helps bridge the gap for infants born by C-section and supports breastfeeding benefits.
Nurturing life, from mom to baby
Download BrochurePUBLICATION : Binda S, Chow-Shi-Yée M, El Salti S, Auclair-Ouellet N, Oula M-L, Carton T, Leuillet S, Tomassi D, Hemmings R, Kadoch I-J. The Effect of Probiotics on Health in Pregnancy and Infants: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2025; 17(11):1825. https://doi.org/10.3390/nu17111825